Search

everythinglearnresearchcommunity

for

Search:↓

The user is considering switching from topical to oral finasteride due to lack of progress with their current hair loss treatment, which includes topical fin/min, microneedling, Nizoral shampoo, oral minoxidil, biotin, collagen, tretinoin, and hair masks. A suggestion was made to try oral finasteride for potentially better results and to monitor progress over 6-12 months.

The user has been using Dutasteride, Minoxidil, Ketoconazole, and RU58841 for hair loss but sees subpar results. Suggestions include adjusting treatments, considering a hair transplant, and addressing scalp inflammation.

The conversation discusses hair loss treatments, focusing on the use of Minoxidil, finasteride, and triamcinolone. Concerns are raised about high concentrations of Minoxidil and the long-term use of corticosteroids.

Treatments for hair loss, focusing on Fluridil/Topilutamide (Eucapil), Finasteride and RU58841 (Alfatradiol). The user reported that the Fluridil seemed to work well but had side effects of testicle ache, decreased mood and sex drive.

RU58841 is considered effective by some users, but finasteride and minoxidil are commonly used with varying dosages to manage side effects. Users report different experiences with treatments like pyrilutamide, fluridil, and RU58841, with some seeing results and others not.

The user is experiencing increased hair loss and was diagnosed with male pattern baldness. They are considering using oral or topical finasteride to manage the condition and are contemplating cutting their hair short.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

A 25-year-old male experiencing hair loss and thinning since age 20 is seeking advice on effective DHT inhibitors. He lists various oral and topical treatments, excluding Minoxidil due to adverse effects.

The conversation is about someone using Dutasteride, oral Minoxidil, and Tretinoin for hair loss, and they also stopped antipsychotics and treated an H. pylori infection. They feel there has been progress in their hair growth over two months.

The user is considering switching from a topical hair loss treatment to oral medication. They currently use a topical solution with Minoxidil, Dutasteride, Finasteride, Tretinoin, and Ketoconazole and are seeking advice on transitioning to oral Dutasteride and Minoxidil.